Last update 01 Nov 2024

Fernando Pessoa University

Education

www.ufp.pt

Education

www.ufp.pt

Last update 01 Nov 2024

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with Fernando Pessoa University

NCT06205069 / CompletedNot ApplicableIIT

The Immediate Effects of Tissue Flossing on Knee Flexion Range of Motion: A Randomized Controlled Trial

The purpose of this study is to verify the immediate effects of Tissue Flossing on knee flexion range of motion

Start Date15 Feb 2024

Sponsor / Collaborator

Fernando Pessoa University

NCT06320977 / CompletedNot ApplicableIIT

The Influence of Acute Static Stretching on the Ankle Joint-position Sense of Soccer Players: a Randomized Controlled Trial

The aim of this study isto investigate the influence of acute static stretching on the ankle joint position sense of soccer players.

Start Date12 Feb 2024

Sponsor / Collaborator

Fernando Pessoa University

NCT06226961 / CompletedNot ApplicableIIT

Immediate Effects of Dynamic Cupping on Shoulder Active Range of Motion of Senior Male Handball Athletes: A Randomized Controlled Trial

The purpose of this study is to to verify the immediate effects of dynamic cupping on shoulder active range of motion (AROM) of senior male handball athletes.

Start Date02 Feb 2024

Sponsor / Collaborator

Fernando Pessoa University

100 Clinical Results associated with Fernando Pessoa University

0 Patents (Medical) associated with Fernando Pessoa University

1,625

Literatures (Medical) associated with Fernando Pessoa University

16 Sep 2024·Minerva medica

Noninvasive tools for the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease.

Article

Author: Oliveira, Raquel ; Martins-Mendes, Daniela ; Passos, Beatriz ; Martins, Maria E ; Rigor, Joana

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously nonalcoholic fatty liver disease (NAFLD), is the number one chronic liver disorder worldwide. Progression to advanced fibrosis marks the emergence of a significant risk of liver-related negative outcomes. However, only a minority of patients will present at this stage. Since widespread liver biopsy in unfeasible at such high disease prevalence, there was a need to develop noninvasive tests (NITs) that could easily and reliably be applied to patients with MASLD, regardless of clinical setting. The NITs include simple scores, like the fibrosis-4 (FIB-4) Index, patented serum tests, like the Enhanced Liver Fibrosis test (ELF™), and imaging-based modalities, like the vibration-controlled transient elastography (VCTE). Guidelines suggests a stepwise approach that utilizes more than one NIT, with FIB-4 <1.30 being used as a first step to rule out patients that do not need further testing. Subsequent choice of NIT will be influenced by setting, cost, and local availability. While these NITs are accurate, they are not perfect. As such, research is ongoing. A promising avenue is that of omics, a group of technologies that provide concomitant results on a large number of molecules (and other variables). With the advance of artificial intelligence, new NITs may arise from large demographic, biochemical, and radiological data sets.

01 Sep 2024·Acta Biomaterialia

Navigating Neurotoxicity and Safety Assessment of Nanocarriers for Brain Delivery: Strategies and Insights

Review

Author: Lopes, Carla M ; Costa, Paulo C. ; Lopes, Carla M. ; Amaral, Maria Helena ; Costa, Paulo C ; Teixeira, Maria Inês

Nanomedicine, an area that uses nanomaterials for theragnostic purposes, is advancing rapidly, particularly in the detection and treatment of neurodegenerative diseases. The design of nanocarriers can be optimized to enhance drug bioavailability and targeting to specific organs, improving therapeutic outcomes. However, clinical translation hinges on biocompatibility and safety. Nanocarriers can cross the blood-brain barrier (BBB), potentially causing neurotoxic effects through mechanisms such as oxidative stress, DNA damage, and neuroinflammation. Concerns about their accumulation and persistence in the brain make it imperative to carry out a nanotoxicological risk assessment. Generally, this involves identifying exposure sources and routes, characterizing physicochemical properties, and conducting cytotoxicity assays both in vitro and in vivo. The lack of a specialized regulatory framework creates substantial gaps, making it challenging to translate findings across development stages. Additionally, there is a pressing need for innovative testing methods due to constraints on animal use and the demand for high-throughput screening. This review examines the mechanisms of nanocarrier-induced neurotoxicity and the challenges in risk assessment, highlighting the impact of physicochemical properties and the advantages and limitations of current neurotoxicity evaluation models. Future perspectives are also discussed. Additional guidance is crucial to improve the safety of nanomaterials and reduce associated uncertainty. STATEMENT OF SIGNIFICANCE: Nanocarriers show tremendous potential for theragnostic purposes in neurological diseases, enhancing drug targeting to the brain, and improving biodistribution and pharmacokinetics. However, their neurotoxicity is still a major field to be explored, with only 5% of nanotechnology-related publications addressing this matter. This review focuses on the issue of neurotoxicity and safety assessment of nanocarriers for brain delivery. Neurotoxicity-relevant exposure sources, routes, and molecular mechanisms, along with the impact of the physicochemical properties of nanomaterials, are comprehensively described. Moreover, the different experimental models used for neurotoxicity evaluation are explored at length, including their main advantages and limitations. To conclude, we discuss current challenges and future perspectives for a better understanding of risk assessment of nanocarriers for neurobiomedical applications.

05 Aug 2024·2024 IEEE 19th Conference on Industrial Electronics and Applications (ICIEA)

Deep Learning for Sustainable Food Systems: Mitigating Climate Change Through Food Waste Reduction

Author: Esho, Esther Oreofeoluwa ; Akinyelu, Andronicus A.

100 Deals associated with Fernando Pessoa University

100 Translational Medicine associated with Fernando Pessoa University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Fernando Pessoa University

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Dec 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing